Key insights
- Wolfe Research initiated coverage of Protagonist Therapeutics (PTGX) with an outperform rating and a $135 price target, citing a strong pipeline and upcoming catalysts. Other analysts have also issued positive ratings and price target increases. While positive for PTGX, the broader market impact is limited, primarily influencing sentiment within the biotech sector.
Investing.com - Wolfe Research initiated coverage on Protagonist Therapeutics Inc. (NASDAQ:PTGX) with an outperform rating and set a price target of $135.00 on Wednesday. The stock currently trades at $100.88, near its 52-week high of $107.84, after delivering a 120% return over the past year.
The research firm cited the company’s early-stage pipeline with what it described as a higher probability of success than industry norms. Wolfe Research pointed to biology that is already well-validated, indications with clear regulatory pathways, and the company’s exclusive focus on peptides.
The firm highlighted an upcoming catalyst-rich period for Protagonist Therapeutics, with clinical proof of concept expected for three wholly-owned assets: PN-881 in the second half of 2026, PN-477sc in the second half of 2026, and PN-8047 in the first half of 2027.
Wolfe Research noted the company’s financial position, citing a royalty stream and milestone payments from Johnson & Johnson (NYSE:JNJ) and Takeda. The firm said Protagonist Therapeutics is slated to receive $475 million in milestones this year from Takeda alone.
The research firm said the company can reach $135 by the end of 2026, representing 34% upside from current levels.
In other recent news, Protagonist Therapeutics has been the focus of several analyst updates and projections. BMO Capital reiterated an Outperform rating on the company, emphasizing the potential for accelerated clinical diversification and growth, backed by a cash position of $620 million as of March 31, 2026. Citizens raised its price target for Protagonist Therapeutics shares to $137, highlighting the success of Icotyde in treating psoriasis and a significant market opportunity projected by partner Johnson & Johnson. Jefferies also maintained a Buy rating, noting Johnson & Johnson’s optimistic earnings report and projections for Icotyde, suggesting it could become one of the company’s largest products with sales exceeding $10 billion.
Truist Securities increased its price target to $121, citing positive feedback from Johnson & Johnson about Icotyde’s rapid adoption in psoriasis treatment. Clear Street raised its price target to $116, following discussions at the AAD conference, and recognized Icotyde’s unique profile as an oral IL-23 treatment. These developments reflect growing confidence in Protagonist Therapeutics’ prospects and the impact of its partnerships and product launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.